Tulio M. Lima

Tulio M. Lima

Auto-generated profile, based on publicly available information

Tulio M. Lima

Cell Culture Engineering Lab., COPPE, Federal University of Rio de Janeiro (UFRJ)

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CCCecilia B. Cavazzoni
Cecilia B. Cavazzoni
VBVicente B.T. Bozza
Vicente B.T. Bozza
TLTostes C.V. Lucas
Tostes C.V. Lucas
LCLuciana Conde
Luciana Conde
BMBruno Maia
Bruno Maia
AVAndre M. Vale
Andre M. Vale
Besides antigen-specific responses to viral antigens, humoral immune response in virus infection can generate polyreactive and autoreactive antibodies. Dengue and Zika virus infections have been linked to antibody-mediated autoimmune disorders, including Guillain-Barré syndrome. A unique feature of flaviviruses is the secretion of nonstructural protein 1 (NS1) by infected cells. NS1 is highly immunogenic, and antibodies targeting NS1 can have both protective and pathogenic roles. In the present study, we investigated the humoral immune response to Zika virus NS1 and found NS1 to be an immunodominant viral antigen associated with the presence of autoreactive antibodies. Through single B cell cultures, we coupled binding assays and BCR sequencing, confirming the immunodominance of NS1. We demonstrate the presence of self-reactive clones in germinal centers after both infection and immunization, some of which present cross-reactivity with NS1. Sequence analysis of anti-NS1 B cell clones showed sequence features associated with pathogenic autoreactive antibodies. Our findings demonstrate NS1 immunodominance at the cellular level as well as a potential role for NS1 in ZIKV-associated autoimmune manifestations.

18 June 2021 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
RARenata G F Alvim
Renata G F Alvim
TLTúlio M. Lima
Túlio M. Lima
JSJerson Silva
Jerson Silva
GOGuilherme de Oliveira
Guilherme de Oliveira
LCLeda R. Castilho
Leda R. Castilho

6 October 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
JDJúlio Souza Dos-Santos
Júlio Souza Dos-Santos
LFLuan Firmino-Cruz
Luan Firmino-Cruz
AMALESSANDRA MARCIA da FONSECA MARTINS
ALESSANDRA MARCIA da FONSECA MARTINS
DODiogo Oliveira-Maciel
Diogo Oliveira-Maciel
GPGustavo Guadagini Perez
Gustavo Guadagini Perez
HGHerbert L. de Matos Guedes
Herbert L. de Matos Guedes
The SARS-CoV-2 pandemic has had a social and economic impact worldwide, and vaccination is an efficient strategy for diminishing those damages. New adjuvant formulations are required for the high vaccine demands, especially adjuvant formulations that induce a Th1 phenotype. Herein we assess a vaccination strategy using a combination of Alum and polyinosinic:polycytidylic acid (Poly(I:C)) adjuvants plus the SARS-CoV-2 spike protein in a prefusion trimeric conformation by an intradermal (ID) route. We found high levels of IgG anti-spike antibodies in the serum by enzyme linked immunosorbent assay (ELISA) and high neutralizing titers against SARS-CoV-2 in vitro by neutralization assay, after one or two boosts. By evaluating the production of IgG subtypes, as expected, we found that formulations containing Poly(I:C) induced IgG2a whereas Alum did not. The combination of these two adjuvants induced high levels of both IgG1 and IgG2a. In addition, cellular immune responses of CD4 + and CD8 + T cells producing interferon-gamma were equivalent, demonstrating that the Alum + Poly(I:C) combination supported a Th1 profile. Based on the high neutralizing titers, we evaluated B cells in the germinal centers, which are specific for receptor-binding domain (RBD) and spike, and observed that more positive B cells were induced upon the Alum + Poly(I:C) combination. Moreover, these B cells produced antibodies against both RBD and non-RBD sites. We also studied the impact of this vaccination preparation (spike protein with Alum + Poly(I:C)) in the lungs of mice challenged with inactivated SARS-CoV-2 virus. We found a production of IgG, but not IgA, and a reduction in neutrophil recruitment in the bronchoalveolar lavage fluid (BALF) of mice, suggesting that our immunization scheme reduced lung inflammation. Altogether, our data suggest that Alum and Poly(I:C) together is a possible adjuvant combination for vaccines against SARS-CoV-2 by the intradermal route.

1 January 2021 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
LCLuis Eduardo R. Cunha
Luis Eduardo R. Cunha
ASAdilson A. Stolet
Adilson A. Stolet
MSMarcelo A. Strauch
Marcelo A. Strauch
VPVictor A. R. Pereira
Victor A. R. Pereira
CDCarlos H. Dumard
Carlos H. Dumard
SASneak Peek Administrator
Sneak Peek Administrator
We used the trimeric spike (S) glycoprotein (residues 1-1208) in the prefusion conformation to immunize horses for the production of hyperimmune globulins against SARS-CoV-2. Serum antibody titers measured by anti-spike ELISA were above 1:106, and neutralizing antibody titer against an early isolate of authentic virus (WT) was 1:14,604 (average PRNT90), which is 140-fold higher than the average neutralizing titer of plasma from three convalescent COVID-19 patients analyzed for comparison. Using the same technology routinely used for industrial production of other horse hyperimmune products, plasma from immunized animals was pepsin digested to remove the Fc portion and purified, yielding an F(ab’)2 preparation with PRNT90 titers 150-fold higher than the neutralizing titers in human convalescent plasma. Repeating the hyperimmunization in a second group of horses confirmed the very high neutralizing titers in serum and in a GMP clinical F(ab’)2 lot. Virus-neutralizing activity in samples from mice that received the F(ab’)22 was similar against WT and P.2 but displaced to higher concentrations by 0.39 log units against P.1. The neutralizing activity against P.1 can be explained by the polyclonal nature of the raised antibody against the whole spike protein. These results support the possibility of using equine F(ab’)2 preparation for the clinical treatment of COVID patients.

1 January 2026 in Canadian Journal of Infectious Diseases and Medical Microbiology
Verified
Journal Article
Open access
PDF file
SCSarah Vieira Contin
Sarah Vieira Contin
BAB. F. Nathalie Almeida
B. F. Nathalie Almeida
SFS. Priscilla Filgueiras
S. Priscilla Filgueiras
ACA. Camila Corsini
A. Camila Corsini
AMA. P. Daniel de Miranda
A. P. Daniel de Miranda
RGRafaella Fortini Queiroz e Grenfell
Rafaella Fortini Queiroz e Grenfell
This two‐year cohort study evaluated immunogenicity, safety, and reactogenicity in 1675 Brazilian healthcare workers who received CoronaVac as a primary protocol (PP) followed by heterologous boosters. All vaccines were safe, with no serious adverse events. Reactogenicity was highest for Ad26.COV2.S (62.86%) as a second booster, followed by Covishield (58.56%) and Comirnaty (42.62%); CoronaVac PP reactogenicity was 19.58%. Total anti‐S IgG levels remained high throughout, increasing after the first booster. At 9 months post‐PP, Comirnaty‐boosted individuals showed superior responses versus CoronaVac alone, regardless of prior infection. No differences were observed between one or two boosters, age groups, or sex. Initially, previously infected participants had higher anti‐S IgG (6–9 months), but this difference disappeared post‐booster. Neutralizing antibodies against Omicron BA.1 were stronger in previously infected individuals at 6–12 months. The first booster increased neutralization in both groups; the second booster further enhanced responses in infection‐naive individuals and maintained them in previously infected participants, with sustained activity up to 24 months. Participants with prior COVID‐19 showed higher levels of immunological biomarkers early on, but this gap closed after the second booster, which elevated biomarkers in both groups. Cellular response, inferred from biomarker interactions, was generally higher in infection‐naive individuals. These results underscore the importance of heterologous booster regimens in sustaining long‐term humoral and cellular immunity against COVID‐19.